Low interest rates and high stock valuations are fueling U.S. life sciences CEOs’ growing appetite for mergers and acquisitions, KPMG’s CEO Outlook found.
“U.S. CEOs are very much attuned to financial markets and the cost of capital,” said Carole Streicher, KPMG LLP’s Deal Advisory leader for healthcare and life sciences. “Investors want to see CEOs maximize returns, whether that is from cutting costs, repurchasing shares, making acquisitions that will immediately boost earnings per share, or gaining a medication, device or technology that can sustain the product pipeline.”
